Quanterix Launches Integrated Spatial Biology Platform for Cancer Research

The platform integrates Akoya’s spatial biology technology with the company’s established expertise in ultra-sensitive, quantitative immunoassay development based on Simoa technology.

Organized around the hallmarks of cancer framework, the system is designed to provide a systematic, biology-first approach for extracting more information from each tissue section. It is paired with assay design and reagent formulation capabilities, along with quality systems and manufacturing scale, to enable measurements suited for translational research and clinical use.

Also being presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting is the PhenoCode Discovery IO60 panel, a finalist for the Edison Awards, alongside a new IO60 Spike-In Module from Quanterix that expands coverage into two high-priority domains. These include checkpoint therapy markers spanning PD-1/PD-L1, CTLA-4, and next-generation blockade, as well as tertiary lymphoid structure markers, an emerging correlate of durable immunotherapy response.

Quanterix will also introduce the PhenoCode Molecular Barcoding Kit, built on PhenoCode 2.0 chemistry, which enables high-reliability, high-yield barcoding of virtually any antibody; early access is set to begin in May 2026. In parallel, the Accelerator Service Lab will present two new antibody-drug conjugate lung cancer panels for PhenoImager HT, both offered as fully managed services, expanding on a breast cancer panel introduced at the AACR 2025 Annual Meeting.

Quanterix’s spatial biology community will also be represented by more than 25 customer and collaborator posters featuring PhenoCycler-Fusion and PhenoImager HT across multiple cancer indications.

“Spatial biology has fundamentally changed how we see cancer. Akoya built a platform that gave researchers an entirely new way to study it. What Quanterix brings is the assay expertise, quality systems, and scale to carry that science further, into translational settings, into the clinic, into decisions that affect patients. The Content Innovation Engine is the first expression of what that combination makes possible,” said Everett Cunningham, President and CEO of Quanterix.

Related Links
Quanterix